Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Other solid neoplasm 1Genitourinary 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Wilms Tumor 1Unspecified Childhood Solid Tumor, Protocol Specific 1Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Retinoblastoma 1Osteosarcoma 1Neuroectodermal Tumors 1Neuroblastoma 1Mesothelioma, Malignant 1Hepatoblastoma 1Adrenocortical Carcinoma 1

Interventions

Granulocyte Colony-Stimulating Factor 2Cyclophosphamide 2racotumomab 1pembrolizumab 1pegylated granulocyte colony-stimulating factor 1omburtamab I-131 1cixutumumab 1Topotecan 1Thiotepa 1Thalidomide 1Sirolimus 1Simvastatin 1Peripheral Blood Stem Cell Transplantation 1Melphalan 1Imatinib Mesylate 1Filgrastim 1Busulfan 1Bone Marrow Transplantation 1Biological Factors 1Amifostine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma, Ewing × cixutumumab × Other solid neoplasm × Clear all
NCT00831844 2015-03-30

Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 2 Completed
116 enrolled 8 charts
CNSEndocrineGastrointestinalGenitourinaryOther solid neoplasmSarcoma

Wilms Tumor, Neuroblastoma, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Neuroectodermal Tumors, Hepatoblastoma, Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡